You are here: Home » Companies » News
Business Standard

Strides Pharma Puducherry unit receives warning letter from USFDA

The drug firm, however, did not provide any details of the contents of the warning letter received from the regulator.

USFDA | Strides Pharma Science

Press Trust of India  |  New Delhi 

Drugs, Pharma, medicine
Representative Image

Drug firm Tuesday the US health regulator has issued a warning letter to the company for its Puducherry facility.

The company has now received a warning letter from the United States Food and Drug Administration (USFDA) relating to the Puducherry facility, said in a BSE filing.

The drug firm, however, did not provide any details of the contents of the warning letter received from the regulator.

The company said its Puducherry site currently produces six products which will not get impacted by the current development.

However, the 10 abbreviated new drug applications (ANDAs) pending approval from the Puducherry facility will get deferred till the site is reclassified, the company added.

Strides said it is committed to the highest standards of quality and compliance, and will work collaboratively with the to resolve all issues addressed in the warning letter.

The company said it retains its growth guidance for the US market.

Earlier, in May 6, 2019, the company had said that the US health regulator had classified its inspection of the company's Puducherry facility as "Official Action Indicated".

Shares of were trading 4.35 per cent lower at Rs 394 apiece on the BSE.   

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Tue, July 02 2019. 12:15 IST